Please wait
Johnson & Johnson (JNJ) is listed on the Nigerian Exchange in the Healthcare sector, with exposure to Drug Manufacturers - General. This page brings together the current share price, valuation, dividend context, business summary, and a practical current view so you can assess the stock faster.
Healthcare
₦913T
2.1%
28.36
Current price
₦381,990.00
Updated Updated just now
Conviction
79/100
Confidence
Low
Market tone
neutral · 79/100
Entry
Medium · 79/100
Recent price action for JNJ, so the page starts with the stock itself before the deeper analysis.
Both size and absolute trading activity suggest this name is usually easier to enter and exit.
Valuation view
Looks relatively cheap vs peers
Income view
Low income profile
Market tone
neutral (79/100) — price action, attention, and recent context all lean here.
Entry view
Medium (79/100) — The company is profitable on the latest reported numbers.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Investors usually follow JNJ for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Director dealings
0
Reported buys, sells, and mixed dealings.
Corporate actions
0
Dividend and company notices.
Market events
0
Insider, filing, dividend, and price events.
Source records
3
Captured updates we can trace.
Whisone is bullish because fundamentals are solid at 79/100 while RSI is hot at 70.9. Whisone has high conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
ROE
26.4%
Return on equity
ROA
8.4%
Return on assets
Debt / equity
0.68
Lower is usually safer.
P/B ratio
33.73
Useful for book value support.
Dividend yield
2.1%
Current income signal.
99/100
Direction
Positive bias
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Valuation still leaves room versus fair value and analyst anchors.
Recent price behavior and momentum still support follow-through.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
₦829,305.00
Analyst view
Buy
Analyst target
₦386,250.00
Forecast refresh
Updated just now
Quality score
77
Growth score
61.5
These are the external analyst numbers and business outlook figures already synced into the company record.
Low target
₦150,300,000,000,000.00
High target
₦153,300,000,000,000.00
Revenue this year
₦151T
Revenue next year
₦161T
EPS this year
₦17,355.00
EPS next year
₦19,050.00
Dividend / share
₦6,285.00
Forward P/E
16.98
US stock catalog seed
Updated 2d ago
Seeded from the built-in US stock catalog for database discovery and later background refresh.
Price points saved
50
Latest market date
2026-06-26
Dividend yield
2.1%
Ex-dividend date
May 26, 2026
Price: ₦381,990.00
P/E: 28.36
Yield: 2.1%
ABBV
AbbVie Inc.
Price: ₦380,025.00
P/E: 124.8
Yield: 2.7%
ABT
Abbott Laboratories
Price: ₦141,180.00
P/E: 26.36
Yield: 2.7%
AMGN
Amgen Inc.
Price: ₦537,495.00
P/E: 24.94
Yield: 2.8%
Industry
Drug Manufacturers - General
Founded
1886
Employees
138,200
Exchange
NYSE
Ticker
JNJ
